Cargando…

MPC-06 Cutting-edge of Cancer Genomic Medicine for brain tumors

Kyushu University Hospital was designated a Cancer Genome Core Hospital in April 2018, and the multi-gene panel test has been introduced since August 2019. The expert panel has been held for 21 cases of the central nervous system (11 adult glioma, 5 pediatric brain tumors, 5 extramedullary tumors)....

Descripción completa

Detalles Bibliográficos
Autores principales:	Mizoguchi, Masahiro, Hata, Nobuhiro, Kuga, Daisuke, Hatae, Ryusuke, Sangatsuda, Yuhei, Fujioka, Yutaka, Takigawa, Kosuke, Funakoshi, Yusuke, Koga, Yuhki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Supplement Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699069/ http://dx.doi.org/10.1093/noajnl/vdaa143.051

Ejemplares similares

ACT-02 Changes in Recurrence Pattern and Prognosis of Glioblastoma after Approval of Bevacizumab as First-line Application
por: Funakoshi, Yusuke, et al.
Publicado: (2020)

Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma
por: Funakoshi, Yusuke, et al.
Publicado: (2020)

Pediatric Glioma: An Update of Diagnosis, Biology, and Treatment
por: Funakoshi, Yusuke, et al.
Publicado: (2021)

Current trend in treatment of glioblastoma in Japan: a national survey using the diagnostic procedure combination database (J-ASPECT study-glioblastoma)
por: Funakoshi, Yusuke, et al.
Publicado: (2021)

Molecular diagnosis of diffuse glioma using a chip-based digital PCR system to analyze IDH, TERT, and H3 mutations in the cerebrospinal fluid
por: Fujioka, Yutaka, et al.
Publicado: (2021)

Supramaximal Resection Can Prolong the Survival of Patients with Cortical Glioblastoma: A Volumetric Study
por: OTSUJI, Ryosuke, et al.
Publicado: (2023)

Volumetric study reveals the relationship between outcome and early radiographic response during bevacizumab-containing chemoradiotherapy for unresectable glioblastoma
por: Takigawa, Kosuke, et al.
Publicado: (2021)

ACT-16 THE POTENTIAL OF HYPOFRACTIONATED RADIOTHERAPY AND BEVACIZUMAB FOR GLIOBLASTOMA TREATMENT
por: Hata, Nobuhiro, et al.
Publicado: (2019)

Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH‐wildtype glioblastoma
por: Funakoshi, Yusuke, et al.
Publicado: (2021)

Mesenchymal glioblastoma-induced mature de-novo vessel formation of vascular endothelial cells in a microfluidic device
por: Amemiya, Takeo, et al.
Publicado: (2021)

Liquid biopsy with multiplex ligation-dependent probe amplification targeting cell-free tumor DNA in cerebrospinal fluid from patients with adult diffuse glioma
por: Otsuji, Ryosuke, et al.
Publicado: (2022)

IM-03 CD206 expression in peripheral blood-derived induced-microglia-like cells as a surrogate biomarker for the specific immune microenvironment of glioma
por: Hata, Nobuhiro, et al.
Publicado: (2020)

Add-on bevacizumab can prevent early clinical deterioration and prolong survival in newly diagnosed partially resected glioblastoma patients with a poor performance status
por: Hata, Nobuhiro, et al.
Publicado: (2017)

CD206 Expression in Induced Microglia-Like Cells From Peripheral Blood as a Surrogate Biomarker for the Specific Immune Microenvironment of Neurosurgical Diseases Including Glioma
por: Tanaka, Shunya, et al.
Publicado: (2021)

Base-resolution methylomes of gliomas bearing histone H3.3 mutations reveal a G34 mutant-specific signature shared with bone tumors
por: Sangatsuda, Yuhei, et al.
Publicado: (2020)

TBIO-08. BASE-RESOLUTION METHYLOMES OF GLIOMAS BEARING HISTONE H3.3 MUTATIONS REVEAL A G34 MUTANT-SPECIFIC SIGNATURE SHARED WITH BONE TUMORS
por: Sangatsuda, Yuhei, et al.
Publicado: (2020)

A case of metastatic brain tumor in the perfusion territory of superficial temporal artery-middle cerebral artery anastomosis
por: Fujioka, Yutaka, et al.
Publicado: (2015)

MPC-5 Characteristics of H3 G34-mutant gliomas
por: Kibe, Yuji, et al.
Publicado: (2021)

Precise Detection of IDH1/2 and BRAF Hotspot Mutations in Clinical Glioma Tissues by a Differential Calculus Analysis of High-Resolution Melting Data
por: Hatae, Ryusuke, et al.
Publicado: (2016)

HGG-24. HIGH-GRADE GLIOMA WITH A NOVEL FUSION GENE OF VCL-ALK
por: Yamamoto, Shunsuke, et al.
Publicado: (2020)

Giant cranial angiolipoma with arteriovenous fistula: A case report
por: Hatae, Ryusuke, et al.
Publicado: (2022)

Deferred radiotherapy and upfront procarbazine–ACNU–vincristine administration for 1p19q codeleted oligodendroglial tumors are associated with favorable outcome without compromising patient performance, regardless of WHO grade
por: Hata, Nobuhiro, et al.
Publicado: (2016)

MPC-04 Utility of comprehensive cancer genome analysis for brain tumors
por: Miwa, Kazuhiro, et al.
Publicado: (2020)

MPC-17 2021 WHO Classification of Tumors of the CNS, 5th ed
por: Komori, Takashi
Publicado: (2021)

MPC-02 Prognostic effects of molecular factors in elderly patients with IDH-wildtype Glioblastomas
por: Fukai, Junya, et al.
Publicado: (2020)

MPC-06 LRG1 HAS MULTIPLE POTENTIAL FOR CLINICOPATHOLOGICAL BIOMARKER OF GLIOBLASTOMA
por: Furuta, Takuya, et al.
Publicado: (2019)

A 0.6 Mpc H i structure associated with Stephan’s Quintet
por: Xu, C. K., et al.
Publicado: (2022)

MPC-11 Comprehensive gene expression analysis of IDH-mutated astrocytomas with 19q-loss
por: Otani, Ryohei, et al.
Publicado: (2020)

MPC-4 Malignant transformation of diffuse low-grade gliomas: systematic review and meta-analysis
por: Nakasu, Satoshi, et al.
Publicado: (2021)

MPC-08 Molecular risk stratification using genome-wide DNA methylation data of standard-risk medulloblastomas treated with 18-Gy craniospinal irradiation
por: Irikura, Tomoya, et al.
Publicado: (2020)

Current Trends and Healthcare Resource Usage in the Hospital Treatment of Primary Malignant Brain Tumor in Japan: A National Survey Using the Diagnostic Procedure Combination Database (J-ASPECT Study-Brain Tumor)
por: YOSHIMOTO, Koji, et al.
Publicado: (2016)

MPC-2 Clinical course and prognosis of lower-grade glioma, IDH wildtype and pTERT mutant
por: Takahashi, Yoshinobu, et al.
Publicado: (2021)

MPC-1 DNA methylome analysis suggested the presence of “true” IDH-wildtype lower-grade gliomas
por: Satomi, Kaishi, et al.
Publicado: (2021)

MPC-13 The evaluation of the shift of trend in lower grade glioma diagnoses based on each era`s criteria
por: Pareira, Eriel Sandika, et al.
Publicado: (2021)

Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma
por: Yoshimoto, Koji, et al.
Publicado: (2012)

MPC-10 Prognostic analysis in IDH mutant astrocytoma patient with CDKN2A/B homozygous deletion
por: Yanagisawa, Shunsuke, et al.
Publicado: (2021)

MPC-7 Clinical features of Diffuse hemispheric glioma, H3 G34-mutant in children and young adults
por: Takeshima, Yuki, et al.
Publicado: (2021)

MPC-6 Clinical significance of whole chromosomal aberration signatures in non-metastatic medulloblastomas treated with 18Gy of craniospinal irradiation
por: Fukuoka, Kohei, et al.
Publicado: (2021)

Papillary craniopharyngioma coexisting with an intratumoral abscess in a pediatric patient: A case report and review of the literature
por: Takagi, Katsuhiro, et al.
Publicado: (2021)

RADI-06. Gamma knife surgery for brain stem metastases
por: Tan, Choo Heng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lgo4e156o4ne4969o842p4jn07